Lung Cancer Update Think Tank 1

Lung Cancer Update
A Continuing Medical Education Audio Series

OVERVIEW OF ACTIVITY

Lung cancer is the leading cause of cancer mortality in the United States in both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85 percent of patients who develop lung cancer will die from it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on patient outcomes. However, with the advent of biologic agents, recent improvements have been seen in time to progression and survival in lung cancer clinical trials. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with experts’ perspectives, this CME program is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

LEARNING OBJECTIVES

Critically assess the current utility of EGFR testing (IHC, FISH and mutation analyses) in the selection of treatment for patients with non-small cell lung cancer (NSCLC).
Identify patients with Stage IB NSCLC who may benefit from adjuvant chemotherapy.
Formulate individualized treatment plans addressing the first-, second- and third-line management of recurrent or progressive NSCLC, considering unique patient and tumor characteristics.
Compare and contrast the efficacy and toxicity profiles of bevacizumab and cetuximab when selecting a front-line chemobiologic regimen for patients with metastatic NSCLC.
Define the relative and absolute contraindications for the safe use of bevacizumab in the systemic management of lung cancer.
Critically evaluate the current role (on and off protocol) and scientific rationale for the integration of biologic agents into the multimodality treatment of locally advanced Stage III NSCLC.
Counsel appropriately selected patients with lung cancer about participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located on our website at LungCancerUpdate.com/ThinkTank.

This program is supported by educational grants from Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology/OSI Oncology, ImClone Systems Incorporated, Pfizer Inc and Sanofi-Aventis.

Table of Contents

Top of Page